Zai Lab's oncology segment is dedicated to the discovery, development, and commercialization of innovative cancer therapies. This segment focuses on addressing unmet medical needs in various cancer types, including lung cancer, gastric cancer, and gastrointestinal stromal tumors (GIST). Key activities include clinical trials for drugs like Adagrasib and Bemarituzumab, as well as commercialization of products like Qinlock and Optune. The company leverages precision medicine approaches to target specific genetic mutations and pathways involved in cancer progression. Zai Lab's oncology pipeline aims to improve patient outcomes and quality of life through targeted therapies and breakthrough treatments. Strategic collaborations and partnerships are essential for expanding the oncology portfolio and accelerating drug development.

This segment focuses on developing and commercializing therapies for autoimmune and inflammatory disorders. Research and development efforts are directed towards identifying novel targets and developing innovative treatments for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Zai Lab utilizes advanced technologies, including monoclonal antibodies and small molecules, to modulate the immune system and reduce inflammation. Clinical trials are conducted to evaluate the safety and efficacy of potential therapies, with a focus on improving patient outcomes and quality of life. The company's market positioning in this segment is strengthened by strategic partnerships and collaborations with leading research institutions and pharmaceutical companies. Future opportunities include expanding the pipeline with novel therapies and addressing unmet needs in specific autoimmune and inflammatory conditions.

Zai Lab's infectious diseases segment is dedicated to developing and commercializing therapies for serious bacterial infections. This includes research and development of novel antibiotics and antimicrobial agents to combat drug-resistant bacteria. The company focuses on addressing unmet medical needs in acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Key activities include clinical trials for drugs like NUZYRA and Sulbactam/durlobactam, as well as commercialization efforts to ensure patient access to these life-saving therapies. Zai Lab's market positioning in this segment is strengthened by strategic partnerships and collaborations with leading research institutions and pharmaceutical companies. Future opportunities include expanding the pipeline with novel therapies and addressing emerging infectious disease threats.

The neurology segment at Zai Lab focuses on developing and commercializing therapies for neurological and psychiatric conditions. This includes research and development efforts targeting diseases such as schizophrenia and other neurological disorders. The company utilizes innovative approaches, including novel drug candidates like KarXT, to address unmet medical needs in these areas. Clinical trials are conducted to evaluate the safety and efficacy of potential therapies, with a focus on improving patient outcomes and quality of life. Zai Lab's market positioning in this segment is strengthened by strategic partnerships and collaborations with leading research institutions and pharmaceutical companies. Future opportunities include expanding the pipeline with novel therapies and addressing emerging challenges in neurological and psychiatric care.